Puma Biotechnology, Inc. (PBYI): Capital Expenditures
$71.0K
Year ended 2025-12-31
+9.1%
5-year compound annual growth
-23.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.0K | +26.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $56.0K | -60.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $140.0K | n/a | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $0 | n/a | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $0 | -100.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $46.0K | -85.0% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $306.0K | -30.3% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $439.0K | +1.9% | 2019-03-01, From 2018-01-01 |
| 2017-12-31 | $431.0K | -89.9% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $4.29M | +327.8% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $1.00M | -8.9% | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | $1.10M | +76.3% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $624.0K | n/a | 2016-02-29, From 2013-01-01 |
| No annual figure between 2011-12-31 and 2013-12-31. | |||
| 2011-12-31 | $253.3K | n/a | 2012-03-29, From 2011-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $71.0K | +26.8% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $87.0K | -75.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $291.0K | +781.8% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $2.37M | -38.6% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $998.0K | +103.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗